Skip to content

A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)‐ and psilocybin‐related death in Australia

Shane Darke, Johan Duflou, Amy Peacock, Michael Farrell, Wayne Hall, Julia Lappin

Addiction May 21, 2024 DOI: 10.1111/add.16518 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Retrospective exploratory study Peer reviewed
Sample size 43
Population Cases of LSD- and psilocybin-related death in Australia, 2000–23
Duration 2000–23
Topics LSD Psilocybin
Keywords Toxicology Hallucinogen Pharmacology
Citations 14
Key points LSD- and psilocybin-related death in Australia from 2000 to 2023 was primarily due to traumatic injury from accident or self-harm, with acute toxic reactions solely attributable to LSD being rare.

Abstract

Abstract Background and aims Lysergic acid diethylamide (LSD) and psilocybin are used as recreational drugs, and there is renewed interest in their clinical use. The current study aimed to (1) determine the circumstances of death and case characteristics of LSD‐ and psilocybin‐related death in Australia, 2000–23; and (2) determine the toxicological profile and major autopsy findings of these cases.

Methods: This was a retrospective exploratory study of all cases of LSD‐ and psilocybin‐related death in Australia, 2000–23, retrieved from the National Coronial Information System.

Results: A total of 43 cases were identified: 33 LSD and 10 psilocybin. The median ages were 24 years [interquartile range (IQR) = 13, range = 16–53] (LSD) and 26 years (IQR = 18.5, range = 20–58) (psilocybin), and fewer than five cases were female. The most common circumstance of death among both groups was traumatic accident (LSD 36.4%, psilocybin 40.0%). There were 12 cases of self‐harm, all of which involved LSD, all by physical means. In a fifth, death was attributed to multiple drug toxicity (LSD 18.2%, psilocybin 20.0%). In one case, death was attributed solely to LSD toxicity, while in a further two cases death was attributed to a cardiovascular event following LSD consumption (one LSD only, one multiple drug toxicity). In four psilocybin cases, the cause of death was undetermined. The most common clinical presentation was severe agitation (LSD 27.3%, psilocybin 20.0%). Median blood concentrations were LSD 0.8 μg/l (IQR = 1.7, range = 0.1–3), psilocin 20 μg/l (IQR = 53.5, range = 6–83). LSD was the only drug present in 25.0% of LSD cases and psilocybin in 20.0% of psilocybin cases. Pre‐existing organ pathology was uncommon.

Conclusions: Lysergic acid diethylamide (LSD)‐ and psilocybin‐related death in Australia from 2000 to 2023 was primarily due to traumatic injury, whether through accident or self‐harm. Cases of acute toxic reactions that were attributed solely to LSD were rare.

Comparable studies

Other observational and cohort studies on LSD, most cited first.

Study Year Design Participants
Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. Human participants 2016 Observational cohort
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin Humans 2017 Observational study
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. USA adult respondents from the National Survey on Drug Use and Health (2008-2012) 2015 Observational cohort n = 190,000
Psychedelics not linked to mental health problems or suicidal behavior: A population study Randomly selected United States adults 2015 Observational cohort n = 135,095
Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD. Healthy human participants 2018 Observational study with computational modeling

Citations in the library

Explore topics